Current Report Filing (8-k)
November 02 2022 - 04:07PM
Edgar (US Regulatory)
false000177078700017707872022-11-022022-11-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 2,
2022
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware
|
001-39035
|
45-5614458
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area
code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e- 4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol
|
|
Name of each exchange
on which registered
|
|
Class A common stock, par value $0.00001 per
share
|
|
TXG
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
On November 2, 2022, 10x Genomics, Inc. (the “Company”) issued a
press release announcing the Company’s financial results for the
quarter ended September 30, 2022. A copy of the press release
is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current
Report on Form 8-K and the press release attached as
Exhibit 99.1 hereto shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference into any other filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit No.
|
|
Description of Exhibits
|
|
|
|
|
|
|
|
99.1 |
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL
document). |
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
10x Genomics, Inc.
|
|
|
|
|
By:
|
/s/ Eric S. Whitaker
|
|
Name:
|
Eric S. Whitaker
|
|
Title:
|
Chief Legal Officer |
|
|
|
|
Date: November 2, 2022 |
|
|
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Feb 2023 to Mar 2023
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2022 to Mar 2023
